U.S. Pain Management Drugs Market by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Anti-Migraine, Antidepressants, Opioids, and Non-narcotic Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Back Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Strain, Acute Appendicitis and Others), Type (Chronic Pain and Acute Pain)- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The U.S. Pain Management Drugs market size was exhibited at USD 26.07 billion in 2022 and is projected to hit around USD 36.78 billion by 2032, growing at a CAGR of 3.5% during the forecast period 2023 to 2032.

Pain is defined as an unpleasant sensory and emotional experience conveyed to the brain by sensory neurons, which causes actual or potential tissue damage. The length of the pain can range from acute pain for short term to chronic pain for long term. Acute pain is a sudden onset of pain while chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain by using a given range of medications. Pain management is a medical approach that draws on disciplines in science and alternative healing to study the prevention, diagnosis, and treatment of pain.

Report Scope of the U.S. Pain Management Drugs Market

Market Dynamics

Growth & innovations in the pharmaceutical industry for the manufacturing of pain-relieving drugs owing to massive pool of health-conscious consumers creates an opportunity for the U.S. pain management drugs market. Also, the growth of the U.S. pain management drugs market is expected to be driven by rise in pain disorders, availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of chronic diseases cases in geriatric population, and surge in demand for effective pain medicines with less side effects. Furthermore, the healthcare industry in the U.S. is developing at a significant rate, owing to rise in demand for enhanced healthcare services, significant investments by the government to improve healthcare infrastructure, and development of the medical tourism industry in various cities of the U.S.

As elderly people experience chronic pain due to joint disorders, various surgeries various pain medications are prescribed, which contributes to growth of U.S. pain management drugs market. In U.S., rise in number of diabetic neuropathies is observed, which leads to pain, thus, driving the market growth. For instance, according to an article published in National Library of Medicine 2022, increase in diabetic neuropathic cases was observed from 32 million in 2019 to 88 million in U.S. which drives the market growth.  

Further, increase in incidence of sport injuries is expected to fuel the growth of market. For instance, according to article published in National Library of Medicine 2022, stated that 4.5 million injuries were reported in 2020 with 22% being brain injuries. In addition, rise in prevalence of low back pain cases in adults is increasing contributing to market growth. For instance, according to article published in Springer 2022, stated that 55% adults suffer from back pain with 24 – 80% reoccurrence pain disorder in one year.

In addition, surge in government spending on pain management treatment further fuels the market growth. For instance, according to Journal of Pain 2020, spending on chronic pain in the U.S. in one year is usually $636 billion. Furthermore, various organizations along with the government provide funding for pain management, which is anticipated to contribute to market growth. For instance, according to article published, Congressionally Directed Medical Research Programs 2022, stated that funding of $250,000 is provided to support and promote innovative, high-impact research for the development and management of chronic pain.

Further, rise in prevalence of muscle strain disorders such as neck pain, shoulder, groin pain, and hamstring also require pain medications. For instance, according to article published in National Library of Medicine 2021, patients with muscle strain are prescribed NSAIDs and acetaminophen for 2 to 4 weeks, depending upon the pain condition. Thus, such muscle disorders fuel the growth of the market. In addition, rise in prevalence of acute appendicitis in the U.S. is anticipated to contribute to growth of pain management drugs market. For instance, according to article published in Single care 2021, stated that around 7 in 100 people in U.S., will experience acute appendicitis at some point and is usually common in age between 10 to 30.

Various organizations along with government are counselling people regarding the pain disorders with proper management. E-commerce (electronic commerce) has become a vital tool for small and large businesses globally, due to rise in preference of consumers for online shopping over traditional purchasing methods. Various animations through health apps to educate people regarding dose and frequency of pain medication has contributed to growth of this U.S. pain management drugs market. Moreover, increase in promotional activities by manufacturers and growth in awareness for proper treatment medications for pain disorders among the general population are expected to fuel their adoption in the near future.

Further, availability of various alternative therapies like pain management devices chiropractic manipulation and acupuncture is anticipated to hamper the growth of market. In addition, various side effects of drugs, misuse and habit-forming drugs restrain the market growth. Furthermore, various new advancements like innovative technologies and strategies to formulate drugs which are abuse-deterrent and having long duration effect provide lucrative opportunities to the market players.

The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. The U.S. pain management drugs market experienced a decline in 2021 due to global economic recession led by COVID-19. In addition, the COVID-19 outbreak disrupted the supply chain of pain drugs across various end-user industries like hospitals and pharmacies.

However, the market is anticipated to witness recovery in 2022, and show stable growth for U.S. pain management drugs market in the coming future. This is attributed to the increase in adoption of various pain medications with less side effects, rise in number of pending surgeries, increase diabetes disorders, proper counselling for post operative pain conditions and drug approvals for new pain disorders, drive the market growth.

Segmental Overview

The U.S. pain management drugs market is segmented into drug class, indication, and type of pain. On the basis of drug class, the market is categorized into non-steroidal anti-inflammatory drugs (NSAIDS), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis, and others. Further, it is subdivided into drug class for each indication. On the basis of pain type, the market is segmented bifurcated into chronic and acute pain.

By drug class: 

depending on drug class, the market is bifurcated into non-steroidal anti-inflammatory drugs (NSAIDS), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. The opioids segment exhibited highest growth in 2022 and is expected to remain dominant during the forecast period, owing to use of these medications for major pain conditions and awareness regarding opioids.

By indication: 

On the basis of indication, the market is classified into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis, and others. The postoperative pain segment dominated the market in 2022. This is attributed to rise in number of lifesaving surgeries contributing to growth of the market. Moreover, cancer pain segment is projected to register a highest CAGR during the forecast period, owing to rise in prevalence of cancer cases in U.S.

By pain type: 

On the basis of pain type, the market is segmented into chronic pain and acute pain. The chronic pain segment exhibited highest revenue and is projected to register highest CAGR in 2022, owing to higher prevalence of chronic pain conditions like back pain, pain related to cardiovascular diseases and rise in number of geriatric populations suffering from chronic pain in the U.S.

Presence of several major players, such as Pfizer Inc, Viatris (Mylan N.V.), Eli Lilly and Company, and advancement in manufacturing technology for pain medications in the U.S., drive the growth of the market. In addition, various private organizations organize educating camps for effective pain management treatment across the U.S., marked the growth of this market. For instance, in August 2022, Myovant Sciences, and Pfizer received U.S. FDA Approval for Myfembree, a once-daily treatment for the management of moderate to severe pain associated with endometriosis.

Presence of well-established healthcare infrastructure, and rise in adoption rate of various new pain medications are expected to drive the market growth. Furthermore, agreement as key strategy adopted by the key players in this U.S., further boost the growth of the market. For instance, in May 2021, Eli Lilly announced a licensing agreement to acquire exclusive U.S. rights for CNTX-0290 from Centrexion Therapeutics Corporation. Centrexion mainly focused on developing non-opioid, non-addictive therapeutics for treatment of chronic pain through research and development initiatives that will lead to important clinical advances.

U.S. is expected to grow at the CAGR of 3.5% during the forecast period. The market growth in U.S., is attributable to presence of key players in the region. Moreover, rise in adoption of various formulations for pain management drive the growth of the market. U.S. has high number cancer cases detected, and high percentage of people experience cancer pain which fuels the growth of the market. U.S. offers profitable opportunities for key players operating in the pain management drugs market, owing to the growing infrastructure of industries, rising in spending for pain disorders, as well as well-established presence of domestic companies in the region. In addition, rise in contract manufacturing organizations within the U.S. provides great opportunity for new entrants in this region.  

Some of the prominent players in the U.S. Pain Management Drugs Market include:

• ABBOTT LABORATORIES
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• ELI LILY AND COMPANY
• GLAXOSMITHKLINE PLC (GSK)
• JOHNSON & JOHNSON 
• MERCK & CO. INC.
• MYLAN N.V.
• NOVARTIS INTERNATIONAL AG
• PFIZER INC.
• PURDUE PHARMA L.P.

Segments Covered in the Report

This report forecasts the volume and revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor has segmented the U.S. Pain Management Drugs market.

BY DRUG CLASS

• NSAIDS
• Anesthetics
• Anticonvulsants
• Antimigraine drug
• Antidepressants
• Opioids
• Non-narcotic analgesics

By Indication

• Arthritic Pain
• Neuropathic Pain
• Cancer Pain
• Chronic Back Pain
• Post-operative Pain
• Migraine
• Fibromyalgia
• Bone fracture
• Muscle sprain/strain
• Acute appendicitis
• Others

By Pain Type

• Chronic pain
• Acute pain